



EDCTP

The power of sharing science

EDCTP COVID-19 Emergency Funding Mechanism: Collaborative clinical research studies in sub-Saharan Africa

The EDCTP COVID-19 portfolio


Jean Marie Vianney Habarugira | Senior Project Officer



The EDCTP2 funding programme (2014-2024)


2014-2020

Participating States



€1.17 Bn

- €995 M (in-kind, 280 PSIAs)
- €171.09 M (cash)



€67 M

- €67 M (in-kind, 120 PSIAs)

Third parties



€397 M

- €295.29 M (cash)
- €102.01 M (in-kind)

European Union



€683 M

- €683 M (cash)
Fully committed in work plans 2014-2020

EDCTP-supported activities (#60)


2014-2020

European countries

- | | | |
|------------|-----------------|--------------------|
| 1. Austria | 8. Ireland | 15. Portugal |
| 2. Belgium | 9. Italy | 16. Spain |
| 3. Denmark | 10. Luxembourg | 17. Sweden |
| 4. Finland | 11. Moldova | 18. Switzerland |
| 5. France | 12. Netherlands | 19. United Kingdom |
| 6. Germany | 13. Norway | |
| 7. Greece | 14. Poland | |


African countries

- | | | |
|----------------------------------|-------------------|---------------------------|
| 1. Angola | 16. The Gambia | 31. Rwanda |
| 2. Benin | 17. Ghana | 32. São Tomé and Príncipe |
| 3. Botswana | 18. Guinea | 33. Senegal |
| 4. Burkina Faso | 19. Guinea-Bissau | 34. Sierra Leone |
| 5. Cabo Verde | 20. Ivory Coast | 35. South Africa |
| 6. Cameroon | 21. Kenya | 36. Sudan |
| 7. Central African Republic | 22. Liberia | 37. Tanzania |
| 8. Chad | 23. Lesotho | 38. Togo |
| 9. Comoros | 24. Madagascar | 39. Uganda |
| 10. Congo | 25. Malawi | 40. Zambia |
| 11. Democratic Republic of Congo | 26. Mali | 41. Zimbabwe |
| 12. Equatorial Guinea | 27. Mozambique | |
| 13. Ethiopia | 28. Namibia | |
| 14. Eswatini | 29. Niger | |
| 15. Gabon | 30. Nigeria | |



Country involvement in clinical studies

2014-2020



37 sub-Saharan African countries host recruitment sites of EDCTP-funded collaborative clinical studies

Main funding of COVID-19 research

Schemes existing before COVID-19

- **Epidemic Preparedness Consortia:** research response by consortia funded through an earlier investment of **EUR 20M**:
 - the Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics (**PANDORA-ID-NET**), and
 - the African coalition for Epidemic Research, Response and Training (**ALERRT**).
- Activities include:
 - Immediate initiation of training in lab skills and cases management at points of entry
 - Implementation of Clinical Characterisation Protocol in several countries

New investments from 2020 Work Plan

- **Emergency COVID-19 Call** to support research activities in sub-Saharan Africa to manage and/or prevent the spread of COVID-19
 - As of **Mar 2021, 26** projects with a value of **EUR 12.75M**
- **Other WP2020 calls (under review)** to strengthen the sub-Saharan African research networks and establish an African cohort of epidemiologists and biostatisticians.
 - **EUR 18M** Networks of Excellence
 - **EUR 5M** (jointly with Africa CDC) to train epidemiologists and biostatisticians.
- All 2020 Calls include COVID-19 in the scope
- Existing projects (amendments to incorporate COVID-19 research studies)

Funding Mobilisation to support the COVID-19 Emergency call

From Eur 2.25 M to Eur 12.75 M

- **EDCTP Work Plan 2020 (drafted in 2019)**
(<https://www.edctp.org/web/app/uploads/2020/05/EDCTP2-Work-plan-2020-web.pdf>)
- **Objective:** In case of a public health emergency (such as a Public Health Emergency of International Concern (PHEIC) according to the World Health Organization, a public health emergency under Decision 1082/2013/EU or under applicable national frameworks and regulations),...
- **Indicative timetable:** Will depend on the Public Health Emergency.
- **Indicative budget: EUR 2,25M**


The EDCTP COVID-19 Emergency Call

The four thematic research gaps targeted by the call

- Understanding of the natural history of infection, improve surveillance capabilities, and the role of asymptomatic infection in transmission.
- Promote the development, adaptation, evaluation, and implementation of point-of-care diagnostic tests that can be used to screen all patients presenting with a history consistent with COVID-19 infection.
- Support standardized implementation of randomised, controlled trials for diagnostics and therapeutics on promising products
- Validation and adaptation of existing serological tests and establishment of biobanks and serum panels of well characterised COVID-19 sera.


Mobilisation of funding for COVID-19 research in sub-Saharan Africa

Call timelines and budget



Continued Mobilisation of funding


Demand vs. Offer



Total budget (Mar 2021): **EUR 12.75M** (EUR 2.25M from EU/Horizon 2020 and EUR 10.50M cofunding from Austria, France, Norway Sweden, Portugal, South Africa, Switzerland and the United Kingdom),

COVID-19 Emergency Call - The North-South collaboration

23 (of 26) multi-country consortia, 13 led by sub-Saharan African institutions



COVID-19 Emergency Call

The top 23 projects grouped by thematic topics

Topic 3: Studies contributing to the implementation of randomised, controlled **trials for diagnostics and therapeutics.**

3 RIA2020EF-2968: **BCG revaccination**
RIA2020EF-3049: **BCG revaccination**
RIA2020EF-2975: **platform for clinical trials**

RIA2020EF-2928: **Clin Characterisation**

RIA2020EF-2981: **household transmission**
RIA2020EF-2983: **PCR, influenza system repurpose**

RIA2020EF-2947: **COVID-19 Ag Respi-Strip™**

1

Topic 1: Studies contributing to better understanding of the natural history of infection; improving **surveillance capabilities** and understanding of the role of asymptomatic infection in transmission.

RIA2020EF-2905: **combination of RDTs**
RIA2020EF-2918: **POC-LAMP (PATHPOD) diagnostics**
RIA2020EF-2937: **RT-PCR in a suitcase**

2

Topic 4: Validation and adaptation of existing **serological tests** and establishment of **biobanks and serum panels** of well characterised COVID-19 sera.

RIA2020EF-3042: **antibody & other immunological assays**
RIA2020EF-2977: **Novel Serological Test**

4

















































RIA2020EF-2923: **active epi surveillance**
RIA2020EF-2926: **COVID in pregnant women**
RIA2020EF-2961: **PCR**
RIA2020EF-3008: **antibody evolution following exposure**
RIA2020EF-3012: **COVID-19 Ag Respi-Strip™**

RIA2020EF-3004: **Ag, Ab tests, Xpert® MTB/RIF-Covid and computer aided diagnostic software**
RIA2020EF-3026: **Dried Plasma Spot samples**
RIA2020EF-3030: **RT-LAMP diagnostic**
RIA2020EF-3031: **population-based surveillance**




Topic 2: Development, adaptation, evaluation, and implementation of **point-of-care diagnostic tests.**

The COVID-19 portfolio


Interventions and diseases in 22 (of 26) Grants

AfriCoVER Belgium, France, Mozambique, Netherlands	 	HALT_COVID-19 Denmark, Germany, Netherlands, South Africa	 	AfriDx Denmark, Ghana, Sweden, United Kingdom	 	RE-BCG-CoV-19 Netherlands, South Africa, Spain, Sweden	 
COREP Australia, Germany, Kenya, South Africa, Spain, United States	 	CSIGN Ghana, Spain, United Kingdom	 	Profile-Cov Ethiopia, Netherlands, United Kingdom	 	BCG-COVID-RCT Cape Verde, Denmark, Guinea-Bissau, Mozambique, Portugal	  
TREATS-COVID France, Netherlands, United Kingdom, Zambia	  	STREESCO Benin, Burkina Faso, France, Spain	 	COVADIS Belgium, Burkina Faso, The Gambia, Netherlands, United Kingdom	 	ANTICOV DR Congo, Kenya, Spain, Switzerland, United Kingdom	 
AIDCO Ethiopia, Gabon, Germany, Netherlands, Senegal	 	ITAIL-COVID-19 Belgium, Congo, France, Germany, United Kingdom	 	ASCENT Burkina Faso, France, Guinea, Netherlands, South Africa, Switzerland	 	TraCE Netherlands, South Africa, United Kingdom	  
periCOVID-Africa The Gambia, Kenya, Malawi, Mozambique, Norway, Uganda, United Kingdom	  	RADIATES Consortium South Africa, Sweden, United Kingdom	 	ImmunoCoV Kenya, Netherlands, Sweden	 		
Covid-19 HCW France, South Africa, United Kingdom	 	Africa_Suitcaslab DR Congo, Germany, Ghana, Madagascar, Nigeria, Senegal, Sudan, Uganda, United Kingdom	 	CAB South Africa, Sweden, Uganda, United Kingdom	 		

Intervention

-  Drugs
-  Diagnostics
-  Vaccines

Other

-  Product-focused implementation research

Disease

-  HIV and HIV-associated infections
-  Tuberculosis
-  COVID-19
-  Lower respiratory tract infections

Details per project are presented in the EDCTP COVID-19 case studies booklet (published on the EDCTP Website)